Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Viruses with RNA Genomes

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

"That's not my silo": Navigating fragmented long COVID care in the mid-Atlantic United States.

SSM. Qualitative research in health·2026

Same author

Flowing differently: exploratory characterization of menstrual effluent compared with peripheral blood.

F&S science·2026

Same author

5' leader defects drive persistent HIV-1 viremia on long-term ART.

Nature communications·2026

Same author

Reply to Soliman et al, Rapid HCV diagnostics: aligning molecular innovation with real-world elimination needs.

The Journal of infectious diseases·2026

Same author

HIV causes global B cell dysregulation and restricts HBV-specific B cell development in an incident HBV cohort.

The Journal of clinical investigation·2026

Same author

Single-cell hepatitis B sequencing reveals distinct viral infection events consistent with superinfection.

The Journal of infectious diseases·2026

Search research articles

Related Experiment Video

Updated: Jan 18, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

A small molecule with larger-than-expected effects on hepatitis B virus.

Ashwin Balagopal¹, Andrea L Cox¹

¹The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Cell Host & Microbe

|January 15, 2026

Summary

A new drug, GLP-26, shows promise for treating chronic hepatitis B virus (HBV) infection. In a specialized mouse model, GLP-26 effectively lowered HBV DNA and surface antigen levels, suggesting a potential functional cure.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Related Experiment Videos

Last Updated: Jan 18, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Area of Science:

Hepatology
Virology
Immunology

Background:

Chronic hepatitis B virus (HBV) infection impacts approximately 250 million individuals globally.
Achieving a functional cure for chronic HBV remains a significant clinical challenge with current therapies.

Purpose of the Study:

To evaluate the efficacy of the capsid assembly modulator GLP-26 in a novel preclinical model of chronic HBV infection.
To assess the impact of GLP-26 on viral markers and host immune responses.

Main Methods:

Development of a double-humanized chronic HBV murine model.
Administration of the capsid assembly modulator GLP-26 to the HBV-infected mice.
Quantification of HBV DNA and surface antigen levels, and assessment of immunomodulatory effects.

Main Results:

GLP-26 treatment led to a significant reduction in circulating HBV DNA.
Treatment with GLP-26 decreased HBV surface antigen levels in the blood.
The drug demonstrated immunomodulatory properties in the chronic HBV model.

Conclusions:

GLP-26 is a promising therapeutic candidate for chronic HBV infection.
The developed humanized mouse model is valuable for testing novel HBV therapeutics.
GLP-26 warrants further investigation for its potential to achieve a functional cure in HBV patients.